Physician profile
Brajesh Bhatla
NPI 1821045600
$5,080.22
in general payments reported to CMS, 2019-2025
26 companies · $619 in 2025
The $619 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $926 · 2020: $307 · 2021: $859 · 2022: $743 · 2023: $997 · 2024: $629 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,098 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,098.28 |
| Education | $146.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $854.71 | 2019-2025 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $781.03 | 2019-2025 | Veltassa |
| Horizon Therapeutics Plc | $676.28 | 2021-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $523.61 | 2019-2025 | Lokelma, Farxiga |
| Fresenius USA Marketing, INC. | $493.07 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $396.06 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $270.93 | 2021-2024 | Lupkynis |
| Baxter Healthcare | $176.14 | 2019 | |
| Glaxosmithkline, LLC. | $169.42 | 2022-2024 | Benlysta, Jesduvroq |
| Amgen INC. | $149.14 | 2021-2025 | Tavneos, Aranesp, Krystexxa |
| Calliditas Therapeutics US INC. | $100.40 | 2023-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.55 | 2025 | Jardiance |
| Novo Nordisk INC | $56.78 | 2024-2025 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $51.43 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $51.12 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $43.50 | 2024-2025 | |
| Travere Therapeutics, INC. | $41.22 | 2023-2025 | |
| Shield Therapeutics INC | $35.25 | 2024 | |
| Mallinckrodt Hospital Products INC. | $28.95 | 2020-2023 | Acthar |
| Ultragenyx Pharmaceutical INC. | $22.40 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.10 | 2025 | Keveyis |
| Ani Pharmaceuticals, INC. | $18.81 | 2024 | Purified Cortrophin Gel |
| Rockwell Medical, INC. | $16.45 | 2019 | |
| Strongbridge US INC. | $15.80 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.20 | 2024 | Dupixent |
| Alexion Pharmaceuticals, INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brajesh Bhatla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.